COVID-19: NEC, SARS-CoV-2 gene analysis results released: NEC OncoImmunity (NOI)
COVID-19: NEC
NEC:
We released the result of gene analysis of new coronavirus (SARS-CoV-2) using AI.
It will be an effort to support vaccine development.
NEC / NEC OncoImmunity AS:
Applying the AI prediction technology used in the development of individualized cancer vaccines, the SARS-CoV-2 genomic sequence is analyzed.
Analyze all proteins using a predictive algorithm.
Prediction algorithm:
Multiple “hot spots” containing overlapping epitopes (objects that can be targets for vaccines) were identified.
In addition, it can be used by many people around the world,
And among the proteins of the virus,
We preferentially select those with few mutations,
To ensure safety, it excludes those that are highly similar to human proteins and those that are expressed in important organs.
PC Watch
https://www.google.co.jp/amp/s/pc.watch.impress.co.jp/docs/news/1249/063/amp.index.html
NEC publishes design blueprints for SARS-CoV-2 vaccines using its AI technology:
Tokyo, April 23, 2020 –
NEC Corporation (NEC; TSE: 6701) today announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines
that can drive potent T-cell responses in the majority of the global population. This initiative by the scientific teams within the NEC Group to help combat outbreaks of COVID-19
and support international vaccine development efforts is led by NEC OncoImmunity (NOI) in collaboration with NEC Laboratories Europe (NLE).
These AI prediction platforms
are based on the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.
During the analysis,
which is published at bioRxiv,
the team analyzed thousands of sequences from the SARS-CoV-2 virus (responsible for causing COVID-19)
and identified epitopes (potential vaccine targets) for the 100 most frequent HLA alleles (diverse immunological makeup) in the global population.
The prediction algorithm
scanned for epitopes across the entire repertoire of proteins in SARS-CoV-2, not only the spike surface protein that gives this family of coronavirus its name.
The team then used this data to identify “hotspots” in the viral proteome that contained overlapping and co-located epitopes from multiple HLA-alleles.
The optimal constellation of “hotspots”
was then selected by their algorithms to generate the optimal immune response with the broadest coverage of the human population,
whilst prioritizing hotspots that occurred in conserved regions of the viral proteome.
These conserved regions are less likely to mutate in future strains. In addition, hotspots containing viral epitopes that had significant similarity with human proteins,
especially those expressed in critical organs, were removed from the vaccine design blueprints to avoid adverse effects.
The analysis
demonstrates the significant capabilities of the NEC Group to leverage their AI platforms to design blueprints for a vaccine
that is safe and efficacious in a global population and could address the current and future divergent strains of the SARS-CoV-2 virus.
NEC is now publishing this research
to support scientific advancements in the field and is ready to start partnering efforts to pursue the development of an effective vaccine targeting the global population.
Press Releases | NEC